JP7794735B2 - 切替え療法によるrmsの治療 - Google Patents
切替え療法によるrmsの治療Info
- Publication number
- JP7794735B2 JP7794735B2 JP2022515966A JP2022515966A JP7794735B2 JP 7794735 B2 JP7794735 B2 JP 7794735B2 JP 2022515966 A JP2022515966 A JP 2022515966A JP 2022515966 A JP2022515966 A JP 2022515966A JP 7794735 B2 JP7794735 B2 JP 7794735B2
- Authority
- JP
- Japan
- Prior art keywords
- ofatumumab
- pharmaceutical composition
- disease
- administered
- administration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025159217A JP2026016387A (ja) | 2019-09-11 | 2025-09-25 | 切替え療法によるrmsの治療 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19196789.2 | 2019-09-11 | ||
| EP19196789 | 2019-09-11 | ||
| EP20154736.1 | 2020-01-30 | ||
| EP20154736 | 2020-01-30 | ||
| PCT/EP2020/075332 WO2021048280A1 (en) | 2019-09-11 | 2020-09-10 | Treatment of rms by switching therapy |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025159217A Division JP2026016387A (ja) | 2019-09-11 | 2025-09-25 | 切替え療法によるrmsの治療 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022548575A JP2022548575A (ja) | 2022-11-21 |
| JP2022548575A5 JP2022548575A5 (cg-RX-API-DMAC7.html) | 2023-09-13 |
| JP7794735B2 true JP7794735B2 (ja) | 2026-01-06 |
Family
ID=72709332
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022515966A Active JP7794735B2 (ja) | 2019-09-11 | 2020-09-10 | 切替え療法によるrmsの治療 |
| JP2025159217A Pending JP2026016387A (ja) | 2019-09-11 | 2025-09-25 | 切替え療法によるrmsの治療 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025159217A Pending JP2026016387A (ja) | 2019-09-11 | 2025-09-25 | 切替え療法によるrmsの治療 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20220298253A1 (cg-RX-API-DMAC7.html) |
| EP (2) | EP3864053B1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7794735B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20220062025A (cg-RX-API-DMAC7.html) |
| CN (3) | CN118436777A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2020344154A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3150947A1 (cg-RX-API-DMAC7.html) |
| DK (1) | DK3864053T3 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2957112T3 (cg-RX-API-DMAC7.html) |
| FI (1) | FI3864053T3 (cg-RX-API-DMAC7.html) |
| IL (1) | IL290619A (cg-RX-API-DMAC7.html) |
| LT (1) | LT3864053T (cg-RX-API-DMAC7.html) |
| MX (1) | MX2022003010A (cg-RX-API-DMAC7.html) |
| SI (1) | SI3864053T1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021048280A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4252847A3 (en) | 2016-08-15 | 2023-11-15 | Novartis AG | Regimens and methods of treating multiple sclerosis using ofatumumab |
| US20220389109A1 (en) * | 2019-09-11 | 2022-12-08 | Novartis Ag | Management of conditions other than multiple sclerosis in ofatumumab-treated patients |
| WO2021204994A1 (en) * | 2020-04-09 | 2021-10-14 | Novartis Ag | Ofatumumab for treating ms while maintaining serum igg |
| CA3215371A1 (en) * | 2021-04-13 | 2022-10-20 | Shibeshih Mitiku BELACHEW | Compositions and methods for treating chronic active white matter lesions / radiologically isolated syndrome |
| CN117529336A (zh) * | 2021-04-14 | 2024-02-06 | 诺华股份有限公司 | 用于治疗亚洲患者的多发性硬化症的奥法木单抗 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100944575B1 (ko) | 2002-10-17 | 2010-02-25 | 젠맵 에이/에스 | Cd20에 대한 인간 모노클로날 항체 |
| UA107557C2 (xx) | 2007-07-06 | 2015-01-26 | Композиція антитіла офатумумабу | |
| AR073295A1 (es) * | 2008-09-16 | 2010-10-28 | Genentech Inc | Metodos para tratar la esclerosis multiple progresiva. articulo de fabricacion. |
| EP2692343A1 (en) * | 2012-08-03 | 2014-02-05 | Forward Pharma A/S | Combination therapy for treatment of multiple sclerosis |
| HK1231413A1 (zh) * | 2014-04-29 | 2017-12-22 | Teva Pharmaceutical Industries Ltd. | 用於治疗具有高残疾状况的复发-缓解型多发性硬化症(rrms)的患者的拉喹莫德 |
| EP4252847A3 (en) * | 2016-08-15 | 2023-11-15 | Novartis AG | Regimens and methods of treating multiple sclerosis using ofatumumab |
-
2020
- 2020-09-10 JP JP2022515966A patent/JP7794735B2/ja active Active
- 2020-09-10 US US17/753,632 patent/US20220298253A1/en active Pending
- 2020-09-10 LT LTEPPCT/EP2020/075332T patent/LT3864053T/lt unknown
- 2020-09-10 EP EP20785440.7A patent/EP3864053B1/en active Active
- 2020-09-10 ES ES20785440T patent/ES2957112T3/es active Active
- 2020-09-10 AU AU2020344154A patent/AU2020344154A1/en active Pending
- 2020-09-10 CN CN202410529206.7A patent/CN118436777A/zh active Pending
- 2020-09-10 CN CN202080064158.9A patent/CN114401742B/zh active Active
- 2020-09-10 CN CN202410529209.0A patent/CN118403156A/zh active Pending
- 2020-09-10 DK DK20785440.7T patent/DK3864053T3/da active
- 2020-09-10 FI FIEP20785440.7T patent/FI3864053T3/fi active
- 2020-09-10 CA CA3150947A patent/CA3150947A1/en active Pending
- 2020-09-10 SI SI202030263T patent/SI3864053T1/sl unknown
- 2020-09-10 EP EP23183390.6A patent/EP4230655A3/en active Pending
- 2020-09-10 KR KR1020227011366A patent/KR20220062025A/ko not_active Ceased
- 2020-09-10 WO PCT/EP2020/075332 patent/WO2021048280A1/en not_active Ceased
- 2020-09-10 MX MX2022003010A patent/MX2022003010A/es unknown
-
2022
- 2022-02-14 IL IL290619A patent/IL290619A/en unknown
-
2025
- 2025-09-25 JP JP2025159217A patent/JP2026016387A/ja active Pending
Non-Patent Citations (4)
| Title |
|---|
| Multiple Sclerosis Journal, 2018, Vol. 24, No. S2, pp. 526-527 |
| Neurology, 2014, Vol. 82, pp. 573-581 |
| Neurology, 2018, Vol. 90, pp. e1805-e1814, Short-form article, Supplementary Methods and Results |
| NOVARTIS, A randomized, double-blind, double-dummy, parallel-group study comparing the efficacy and safety of ofatumumab versus teriflunomide in patients with relapsing multiple sclerosis,2018年08月06日, [retrieved on 2024.06.05], Retrieved from the Internet: <URL: https://cdn.clinicaltrials.gov/large-docs/31/NCT02792231/Prot_001.pdf> |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2020344154A1 (en) | 2022-04-07 |
| EP4230655A2 (en) | 2023-08-23 |
| CN114401742A (zh) | 2022-04-26 |
| CN118403156A (zh) | 2024-07-30 |
| EP3864053B1 (en) | 2023-07-05 |
| DK3864053T3 (da) | 2023-09-11 |
| JP2026016387A (ja) | 2026-02-03 |
| LT3864053T (lt) | 2023-09-11 |
| CN114401742B (zh) | 2024-05-24 |
| SI3864053T1 (sl) | 2023-12-29 |
| CN118436777A (zh) | 2024-08-06 |
| MX2022003010A (es) | 2022-06-02 |
| US20220298253A1 (en) | 2022-09-22 |
| IL290619A (en) | 2022-04-01 |
| CA3150947A1 (en) | 2021-03-18 |
| KR20220062025A (ko) | 2022-05-13 |
| EP4230655A3 (en) | 2023-11-01 |
| FI3864053T3 (fi) | 2023-09-13 |
| EP3864053A1 (en) | 2021-08-18 |
| WO2021048280A1 (en) | 2021-03-18 |
| JP2022548575A (ja) | 2022-11-21 |
| ES2957112T3 (es) | 2024-01-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3864053B1 (en) | Treatment of rms by switching therapy | |
| JP6746495B2 (ja) | ベンラリツマブを使用して喘息の増悪率を低減する方法 | |
| JP2020100653A (ja) | ベンラリツマブによる喘息症状の改善方法 | |
| Lopalco et al. | Effectiveness and safety profile of anakinra in a HLA-B27 positive patient with multiple sclerosis-associated uveitis | |
| CA3229704A1 (en) | Ofatumumab for treating pediatric ms | |
| JP2026009900A (ja) | 血清IgGを維持しながらMSを治療するためのオファツムマブ | |
| US20240228647A1 (en) | Ofatumumab for treating multiple sclerosis in asian patients | |
| CN114375306A (zh) | 奥法木单抗治疗患者中除多发性硬化症以外病症的管理 | |
| AU2018361975A1 (en) | Method of treating tendinopathy using interleukin-17 (IL-17) antagonists | |
| RU2849464C1 (ru) | Лечение rms путем смены терапии | |
| HK40051003B (en) | Treatment of rms by switching therapy | |
| HK40051003A (en) | Treatment of rms by switching therapy | |
| WO2017120261A1 (en) | Methods of treating type 2 diabetes mellitus using glucagon receptor antagonistic antibodies | |
| Mahdavian et al. | Multiple sclerosis: a supplement on the disease state, current therapies, and investigational treatments | |
| CN117813328A (zh) | 用于治疗儿童ms的奥法妥木单抗 | |
| TW202300523A (zh) | 用於治療MS同時維持血清IgG之奧法木單抗(OFATUMUMAB) | |
| Bašić Kes et al. | Preporuke za dijagnostiku i liječenje multiple skleroze | |
| Kerry | Maximizing the Effectiveness of Pharmacotherapeutics |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230905 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20230905 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20240903 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20241125 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20250115 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20250228 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20250527 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20250925 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20251209 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20251218 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7794735 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |